Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLRXNASDAQ:TLSANASDAQ:VLONNASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$4.57+3.4%$3.77$2.30▼$35.60$19.48M1.29231,802 shs56,733 shsTLSATiziana Life Sciences$1.60-3.0%$1.36$0.63▼$1.91$186.96M-0.09473,953 shs175,095 shsVLONVallon Pharmaceuticals$1.40+2.9%$0.67$0.21▼$12.92$18.88M-1.145.78 million shs147,342 shsVSTMVerastem$5.19-2.3%$6.69$2.10▼$9.10$285.19M0.851.16 million shs1.61 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx0.00%-13.61%+25.55%+27.65%-81.46%TLSATiziana Life Sciences0.00%+12.68%+6.67%+44.14%+122.22%VLONVallon Pharmaceuticals+2.94%+6.06%0.00%-80.00%-52.38%VSTMVerastem0.00%-11.73%-35.37%-21.95%+58.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLRXBioLineRx2.6177 of 5 stars3.85.00.00.01.10.00.6TLSATiziana Life Sciences0.9718 of 5 stars0.05.00.00.01.91.70.0VLONVallon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVSTMVerastem3.1852 of 5 stars4.52.00.00.01.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLRXBioLineRx 3.50Strong Buy$26.00468.93% UpsideTLSATiziana Life Sciences 0.00N/AN/AN/AVLONVallon Pharmaceuticals 0.00N/AN/AN/AVSTMVerastem 3.00Buy$13.63162.52% UpsideCurrent Analyst Ratings BreakdownLatest BLRX, VLON, VSTM, and TLSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/30/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/28/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/9/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $14.004/10/2025VSTMVerastemJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/9/2025VSTMVerastemMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.004/2/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/31/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $26.003/24/2025VSTMVerastemGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $14.003/24/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/21/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLRXBioLineRx$28.94M0.67N/AN/A$4.04 per share1.13TLSATiziana Life SciencesN/AN/AN/AN/A$0.04 per shareN/AVLONVallon Pharmaceuticals$100K188.75N/AN/A$0.18 per share7.78VSTMVerastem$10K28,519.05N/AN/A($0.65) per share-7.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLRXBioLineRx-$9.22M-$8.80N/AN/AN/A-15.21%-23.93%-6.80%8/15/2025 (Estimated)TLSATiziana Life Sciences-$11.86MN/A0.00∞N/AN/AN/AN/A6/23/2025 (Estimated)VLONVallon Pharmaceuticals-$7.02M-$0.78N/A∞N/AN/A-230.48%-124.89%N/AVSTMVerastem-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/6/2025 (Estimated)Latest BLRX, VLON, VSTM, and TLSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2025Q1 2025BLRXBioLineRx-$0.84$1.39+$2.23$1.39$7.72 million$11.75 million5/13/2025Q1 2025VSTMVerastem-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A3/20/2025Q4 2024VSTMVerastem-$0.76-$1.33-$0.57-$1.33$0.15 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLRXBioLineRxN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/AVLONVallon PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLRXBioLineRx0.372.272.04TLSATiziana Life SciencesN/A1.021.02VLONVallon PharmaceuticalsN/A2.292.29VSTMVerastem2.773.503.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLRXBioLineRx1.56%TLSATiziana Life SciencesN/AVLONVallon Pharmaceuticals8.74%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipBLRXBioLineRx1.10%TLSATiziana Life Sciences39.82%VLONVallon Pharmaceuticals37.30%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLRXBioLineRx404.26 million4.22 millionOptionableTLSATiziana Life Sciences8116.85 million70.32 millionOptionableVLONVallon Pharmaceuticals313.48 million8.45 millionNot OptionableVSTMVerastem5054.95 million53.80 millionOptionableBLRX, VLON, VSTM, and TLSA HeadlinesRecent News About These CompaniesFinancial Contrast: Verastem (NASDAQ:VSTM) vs. Ensysce Biosciences (NASDAQ:ENSC)June 16, 2025 | americanbankingnews.comVerastem’s SWOT analysis: biotech stock poised for growth amid challengesJune 15, 2025 | investing.comVerastem reports promising cancer drug trial resultsJune 4, 2025 | investing.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) InhibitorJune 4, 2025 | businesswire.comVerastem’s Promising Clinical Advances and Strategic Developments Justify Buy RatingJune 3, 2025 | tipranks.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Buy" from BrokeragesJune 3, 2025 | marketbeat.comVerastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns BullishJune 2, 2025 | msn.comVerastem Announces Strategic Plans in Investor WebcastJune 2, 2025 | tipranks.comWhat's Going On With Verastem Oncology Stock On Monday?June 2, 2025 | benzinga.comVerastem, Inc. (NASDAQ:VSTM) Short Interest UpdateJune 2, 2025 | marketbeat.comVerastem Announces Promising Phase 1 Study ResultsJune 2, 2025 | tipranks.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) InhibitorJune 2, 2025 | businesswire.comInvestors Buy Large Volume of Verastem Call Options (NASDAQ:VSTM)May 31, 2025 | marketbeat.comVSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug ApprovalMay 28, 2025 | zacks.comVerastem Oncology to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | businesswire.comNorthern Trust Corp Boosts Holdings in Verastem, Inc. (NASDAQ:VSTM)May 28, 2025 | marketbeat.com723,806 Shares in Verastem, Inc. (NASDAQ:VSTM) Bought by Woodline Partners LPMay 27, 2025 | marketbeat.comBNP Paribas Financial Markets Makes New $387,000 Investment in Verastem, Inc. (NASDAQ:VSTM)May 27, 2025 | marketbeat.comVerastem’s SWOT analysis: biotech firm’s stock poised for growth amid challengesMay 23, 2025 | investing.comVerastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline ...May 23, 2025 | finance.yahoo.comVerastem expands ambitions with strong pancreatic cancer data at ASCOMay 23, 2025 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings3 Stocks Getting Rare Double Upgrades From AnalystsBy Chris Markoch | June 6, 2025View 3 Stocks Getting Rare Double Upgrades From AnalystsBLRX, VLON, VSTM, and TLSA Company DescriptionsBioLineRx NASDAQ:BLRX$4.57 +0.15 (+3.39%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$4.57 0.00 (-0.11%) As of 06/18/2025 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Tiziana Life Sciences NASDAQ:TLSA$1.60 -0.05 (-3.03%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.66 +0.05 (+3.44%) As of 06/18/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.Vallon Pharmaceuticals NASDAQ:VLONVallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.Verastem NASDAQ:VSTM$5.19 -0.12 (-2.26%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$5.24 +0.05 (+0.94%) As of 06/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
